LCTX Lineage Cell Therapeutics

Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer

Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer
EN
13/10/2020

Underlying

LCTXLineage Cell Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lineage Cell Therapeutics

 PRESS RELEASE
Free
LCTX Lineage Cell Th...

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Fi...

CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today reported its fourth quarter and full year 2024 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “Throughout 2024, we made substantial progress across multiple fronts, advancing our programs, expanding collaborations, and strengthening our balance sheet to support significant anticipated milestones,” stated ...

March 10, 2025 1 EN
 PRESS RELEASE
Free
LCTX Lineage Cell Th...

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provid...

March 5, 2025 1 EN
 PRESS RELEASE
Free
LCTX Lineage Cell Th...

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced today that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. The DOSED study will evaluate the safety and utility of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System), a novel delivery device developed to deliver directly to the area of injury in patients with spinal cord injury...

February 11, 2025 1 EN
 PRESS RELEASE
Free
LCTX Lineage Cell Th...

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual He...

CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11, 2025 at 12:40pm ET. The conference is being held virtually February 11-12, 2025. Interested parties can view a replay of the presentation on the section of Lineage’s website. Additional videos are available on the page of the Lineage websit...

February 4, 2025 1 EN
 PRESS RELEASE
Free
LCTX Lineage Cell Th...

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an additional $6 million in gross proceeds at the closing of the second tranche. In addition, the Company may receive up to an additional $36 millio...

January 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch